Scythian Biosciences (SCYB) Stock Price, News & Analysis

Company Overview

Scythian Biosciences Corp. engages in the research and development of cannabinoid-based combination drug therapies for the treatment of concussions and traumatic brain injury. It also develops drug candidates for the treatment of gastro-intestinal inflammatory issues. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: C$3.46 to C$3.77
• 50-Day Range: C$3.49 to C$3.49
• 52-Week Range: C$1.01 to C$8.61
• Volume: 703,164 shs
• Average Volume: 231,491 shs
• Market Capitalization: C$102.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:SCYB
• CIK: N/A
• Web: scythianbio.com
• Phone: +1-416-3669192
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 29,334,000
• Free Float: N/A
• Market Cap: C$102.38 million
• Optionable: Not Optionable
• Beta: N/A